In this study, we discovered an AKT inhibitor (LAE003/Uprosertib, a close analog of Afursertib) reduced the growth of tumor cells from platinum-resistant and PARP inhibitor-resistant ovarian cancer patients, and additively increased anti-tumor response when combined with PARP inhibitor Olaparib. Here, AKT1 is linked to ovarian carcinoma.